The effects of curcuminoid on esophageal and gastric function in patients with gastroesophageal reflux disease

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20180530008

Enrollment

Registered

2018-05-30

Start date

2018-03-01

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastroesophageal reflux disease (GERD) and acid reflux in the esophagus is excessive. curcuminoid&#44

Interventions

&#45

Anti&#45

OxÂ® in 1 capsule contains curcumin extract equivalent to curcuminoid 250 mg as the main substance and other compounds including colloidal silicon dioxide&#44

small amount of magnesium dioxide. The drug was registered by the Food and Drug Administration on August 3&#44

2013&#44

manufactured by Government Pharmaceutical Organization (GPO) This study was a randomized study. All subjects were randomly assigned to receive either curcumin or placebo by blocked randomizati

Placebo in 1 capsule contains 250 mg microcrystalline cellulose and other compounds including colloidal silicon dioxide&#44

small amount of magnesium dioxide. This study was a randomized study. All subjects were randomly assigned to receive either curcumin or placebo by blocked randomization method to divide patien

Experimental Drug,Experimental Drug

Curcuminoid,Placebo

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients who have been diagnosed with acid reflux for at least 3 months 2. Age 18 - 70 years 3. Have had gastrointestinal endoscopy in the last 6 months prior to study. 4. The results of acid measurement in the esophagus found that acid reflux in the esophagus is excessive.

Exclusion criteria

Exclusion criteria: 1. Surgery in the abdomen except appendicitis, Maternity leave 2. Cancer of the gastrointestinal tract and liver 3. chronic inflammatory bowel disease inflammatory bowel disease 4. Cirrhosis, Chronic kidney disease 5. Depression 6. Upper gastrointestinal endoscopy results in 6 months before admission. The following abnormalities were observed: esophagus, gastric ulcer and duodenal ulcer. 7. Helicobacter pylori infection 8. Patients who take the drug with gastrointestinal effects and can not off the drug during research. 9. There are neurological diseases that can not be evaluated for pain. Uncontrolled psychiatric disorders and may want to adjust the drugs during study. 10. Have allergic curcumin. 11. Eat foods that component curcumin, regularly at least 3 days a week during the 1 month prior to study 12. Patients who can not sign the consent form for study participation.

Design outcomes

Primary

Measure	Time frame
Difference of values measured by 24 hour impedance pH monitoring After 4 weeks of intervention 24 hour impedance pH monitoring	—

Secondary

Measure	Time frame
Gastrointestinal symptoms after drug administration and side effects. After 4 weeks of intervention 24 hour impedance pH monitoring ,The relationship between acid reflux symptoms. After 4 weeks of intervention 24 hour impedance pH monitoring	—

Countries

Thailand

Contacts

Public ContactTanisa Patcharatrakul

Gastroenterology unit, Department of medicine, King Chulalongkorn Memorial

dr_tanisa@yahoo.com084-6653624

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026